Bulk Inquiry
NNC 756
- Odapipam
Axon 1405
CAS:
131796-63-9
- Optical Purity: 99% e.e.
- Soluble in DMSO
- MF: C19H20ClNO2
- MW: 329.82
Description
NNC 756 (Odapipam) is a very high-affinity and selective dopamine D1 receptor antagonist with a reported receptor binding Kd value of 0.18 nM. It is more potent than SCH23390 (Axon 4341).
Odapipam blocks D1-like receptor signaling and has been used in receptor-occupancy and neuroimaging studies. It is a useful comparator for dopaminergic motor, cognitive and psychosis-related pathways.
Key Features
- High-affinity dopamine D1 receptor antagonist
- Reported Kd: 0.18 nM
- Suitable for D1 receptor occupancy studies
- Greater D1 antagonist potency than many classical references
Applications
- D1 receptor binding and functional assays
- Dopamine receptor occupancy research
- Motor and cognitive pathway studies
- Psychosis and antipsychotic pharmacology models
More Information
| Parent CAS No. | 131796-63-9 |
|---|---|
| Chemical Name | (S)-(+)-8-Chloro-5-(2,3-dihydro-benzofuran-7-yl)-3-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol |
| SMILES | [C@@H]1(C2C3OCCC=3C=CC=2)C2C=C(O)C(Cl)=CC=2CCN(C)C1 |&1:0,r| |
| MFCD | N.A. |
| InChi | InChI=1S/C19H20ClNO2/c1-21-7-5-13-9-17(20)18(22)10-15(13)16(11-21)14-4-2-3-12-6-8-23-19(12)14/h2-4,9-10,16,22H,5-8,11H2,1H3/t16-/m1/s1 |
| InChiKey | SKMVRXPBCSTNKE-MRXNPFEDSA-N |
| CID | 132421 |
| Short Description | D1 antagonist |
NNC 756 (Odapipam)
high-affinity dopamine D1 receptor antagonist
NNC 756
Odapipam
NNC756
DRD1
dopamine D1 receptor
D1
Antagonist
dopamine signaling
D1 receptor binding and functional assays
Dopamine receptor occupancy research
Motor and cognitive pathway studies
Psychosis and antipsychotic pharmacology models
cognition
GPCR pharmacology
receptor selectivity
signal transduction
receptor pharmacology
CAS 131796-63-9
Axon Medchem
Axon 1405
Supplier
Vendor
References
- EB Nielsen, PH Andersen. Dopamine receptor occupancy in vivo: behavioral correlates using NNC-112, NNC-687 and NNC-756, new selective dopamine D1 receptor antagonists. Eur. J. Pharmacol. 1992, 219(1), 35-44; ibid 45-52.
- A Abi-Dargham et al. PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756. Synapse. 1999, 32(2), 93-109.
Related Products
Other Categories
Get a Quote for
Loading...


